EUVIMEDEUVIMED entdecken
Crossref

Synthesis and preclinical evaluation of 89Zr-DFO-atezolizumab for immuno-PET imaging in colorectal cancer

Siqi Hao, Yang Jiang, Qian Chen, Qian Zhang, Yan Zhang, Soontaree Sriwongta, Opa Vajragupta, Pornchai Rojsitthisak, Zhi Yang, Hua Zhu

Bioorganic & Medicinal Chemistry Letters · 2026-09 · 138 · 130682

DOI: 10.1016/j.bmcl.2026.130682 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Bioorganic & Medicinal Chemistry Letters, 2026-09. Verfasst von Siqi Hao und 9 weiteren Autor:innen. Beteiligte Einrichtung: GuiZhou University Medical College, Guiyang 550025, Guizhou Province, China; Key laboratory of Carcinogenesis and Translational Research (Ministry of…. Hauptthemen laut MEDLINE: Colorectal Neoplasms, Antibodies, Monoclonal, Humanized, Zirconium, Positron-Emission Tomography. Die Arbeit nennt 29 Literaturangaben. Gefördert von: Peking University, Natural Science Foundation of Beijing Municipality, National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The immune checkpoint programmed ligand 1 (PD-L1) is expressed in various solid tumors and is associated with immunotherapy prognosis. Dynamic assessment of PDL1 expression levels helps identify patients who may benefit from immunotherapy. Atezolizumab is a monoclonal antibody that targets PD-L1 and is used in the treatment of various hematologic malignancies and solid tumors. However, research on colon cancer is lacking. Approximately 85% of colorectal cancer (CRC) patients have the MSS/pMMR (Microsatellite Stable/proficient Mismatch Repair) subtype, which lacks ideal biomarkers for precise and dynamic screening of potential immune-responsive subpopulations and for predicting combination therapy strategies. Currently, the assessment of PD-L1 is limited to biopsy samples. Molecular immuno-PET imaging can provide an effective solution for guiding clinical immunotherapy selection. This study describes the development of 89Zr-DFO-atezolizumab, a PD-L1-targeted immuno-imaging agent, and its evaluation in terms of in vitro and in vivo specificity as well as pharmacokinetics. Tumor uptake and heterogeneity were quantified in mouse models via immuno-PET imaging. PET/CT scans using 89Zr-DFO-atezolizumab revealed a significant difference in tumor uptake between the MC38hPD-L1 model and the MC38 model, and cold anti-atezolizumab effectively blocked this uptake. The preliminary dosimetry study indicated that the organs receiving higher doses are the spleen and the liver. Preclinical PET/CT imaging with 89Zr-DFO-atezolizumab reveals its potential for the non-invasive detection of PD-L1-positive CRC tumors, which holds potential significance for understanding tumor heterogeneity and monitoring early PD-L1 expression changes induced by therapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Colorectal NeoplasmsAntibodies, Monoclonal, HumanizedZirconiumPositron-Emission TomographyRadiopharmaceuticalsAnimalsHumansMiceRadioisotopesB7-H1 AntigenMolecular StructureDose-Response Relationship, DrugStructure-Activity Relationship

Stichwörter der Autor:innen

AtezolizumabColorectal cancerImmumo-PETPD-L1Radiopharmaceuticals

Substanzen

Antibodies, Monoclonal, HumanizedatezolizumabZirconiumZirconium-89RadioisotopesRadiopharmaceuticalsB7-H1 Antigen

Autor:innen und Institutionen

  • GuiZhou University Medical College, Guiyang 550025, Guizhou Province, China; Key laboratory of Carcinogenesis and Translational Research (Ministry of Education), Beijing Key Laboratory of Research, Investigation and Eva…
  • Key laboratory of Carcinogenesis and Translational Research (Ministry of Education), Beijing Key Laboratory of Research, Investigation and Evaluation of Radiopharmaceuticals, NMPA Key Laboratory for Research and Evaluat…
  • Molecular Probes for Imaging Research Network, Faculty of Pharmaceutical Sciences, Chulalongkorn University, Bangkok 10330, Thailand; Faculty of Radiological Technology, Rangsit University, Pathum Thani 12000, Thailand.
  • Molecular Probes for Imaging Research Network, Faculty of Pharmaceutical Sciences, Chulalongkorn University, Bangkok 10330, Thailand; Center of Excellence in Natural Products for Ageing and Chronic Diseases, Chulalongko…
  • GuiZhou University Medical College, Guiyang 550025, Guizhou Province, China; State Key Laboratory of Holistic Integrative Management of Gastrointestinal Cancers, Beijing Key Laboratory of Research, Investigation and Eva…

Förderung

  • Peking University
  • Natural Science Foundation of Beijing Municipality
  • National Natural Science Foundation of China

Zitieren

APA

Hao, S., Jiang, Y., Chen, Q., Zhang, Q., Zhang, Y., Sriwongta, S., Vajragupta, O., Rojsitthisak, P., Yang, Z., & Zhu, H. (2026). Synthesis and preclinical evaluation of 89Zr-DFO-atezolizumab for immuno-PET imaging in colorectal cancer. Bioorganic & Medicinal Chemistry Letters, 138, 130682. https://doi.org/10.1016/j.bmcl.2026.130682

Vancouver

Hao S, Jiang Y, Chen Q, Zhang Q, Zhang Y, Sriwongta S, et al. Synthesis and preclinical evaluation of 89Zr-DFO-atezolizumab for immuno-PET imaging in colorectal cancer. Bioorganic & Medicinal Chemistry Letters. 2026;138:130682. doi:10.1016/j.bmcl.2026.130682

BibTeX
@article{Hao2026,
  author = {Hao, Siqi and Jiang, Yang and Chen, Qian and Zhang, Qian and Zhang, Yan and Sriwongta, Soontaree and Vajragupta, Opa and Rojsitthisak, Pornchai and Yang, Zhi and Zhu, Hua},
  title = {Synthesis and preclinical evaluation of 89Zr-DFO-atezolizumab for immuno-PET imaging in colorectal cancer},
  journal = {Bioorganic & Medicinal Chemistry Letters},
  year = {2026},
  volume = {138},
  pages = {130682},
  doi = {10.1016/j.bmcl.2026.130682}
}
Kostenlos starten →